 |
 |
| The LinkMed portfolio consists of a number of life science companies, several of which are nearing the commercialization phase, while others are already selling their products or services. Between them, these companies account for more than 50 different projects in a wide range of therapeutic areas – from HIV and cancer to eye disease and allergies. |
|
COMPANIES IN SEVERAL SECTORS
In our portfolio there are companies active in different segments of the market.
These companies focus on drug development and biotech – AbSorber, AnaMar, Biovator,
IMED, NovaHep och Recopharma and these operate within medical technology – BioResonator, Likvor, Ortoviva, ONCOlog Medical and Pharmacolog. |
|
MANY COMPANIES, LOWER RISKS
By investing in several companies, we spread risks and reduce our exposure to the development in
individual projects. Our goal is to continually develop and manage between 15 and 20 portfolio companies.
Therefore, we plan to invest in several new companies in the coming years.
|
|
|
|
 |
|
|
|
|
|
|
|
 |
|
For safer infusion and injection treatments.
Operations:
Pharmacolog develops systems for non invasive quality assurance of liquid drugs for infusions and injections.
The system controls both which type of drug it is and the concentrations.
Therapeutic area: Chemotherapy for cancer treatment, intensive care, anesthesia etc.
CEO:
Kjell Westerlund
Chairman:
Lars Martin
Venture manager:
Lars Martin
Ownership stake:
48,0%
Address:
Pharmacolog i Uppsala AB,
Ulltunaallén 2 A, SE-756 51 Uppsala
www.pharmacolog.se
|
|
|
|
 |
|
